The Online Investor
Home
Dividends
25 Safe Dividends
Stock Splits
Mergers & Acquisitions
Mega Mergers
Stock Buybacks
Stock Buybacks
Contrarian Outlook
Stock Option Ideas
Preferred Stock Newsletter
ChartZero.com
IPOs
Secondary Offerings
Top 20 Large Caps
Top 20 Biggest ETFs
Insider Buying
Top 25 Low PE Ratios
Analyst Actions
25 Top Analyst Picks
Articles
CAGR Calculator
Dunnan On Dollars
10 Pot Stocks
ETF Center
Knowledge Center
Retirement Center
Advertising Opportunities
Privacy Policy
Disclaimer Statement
LUMO Buyback image

Lumos Pharma, Inc. Buyback

OLI recorded this information on 8/16/2022

Company: Lumos Pharma, Inc.
Buyback: LUMO buyback
$Amount Authorized: $3,000,000
Buyback Details: Lumos Pharma, Inc. ("The Company," NASDAQ:LUMO), a biopharmaceutical company advancing a novel oral therapeutic candidate, LUM-201, through Phase 2 clinical trials for Pediatric Growth Hormone Deficiency (PGHD), today announced that its board of directors has authorized a share repurchase program to acquire up to $3 million of the Company's common stock. The Company may purchase common stock on the open market, through privately negotiated transactions, or otherwise, in compliance with the rules of the United States Securities and Exchange Commission and other applicable legal requirements. As of June 30, 2022, the Company had approximately $79.5 million of cash, cash equivalents, and marketable securities. The Company had approximately 8.4 million shares outstanding as of August 3, 2022.

Lumos Pharma is a clinical-stage biopharmaceutical company. Co. is engaged in developing its clinical program and focused on identifying, acquiring, developing, and commercializing products and therapies for people with rare diseases. Co.'s pipeline is focused on the development of an orally administered small molecule, LUM-201, which is a growth hormone secretagogue, also called ibutamoren, for rare endocrine disorders where injectable recombinant human growth hormone is approved. Co. has two small-molecule product candidates, which include indoximod, NLG802 (a prodrug of indoximod) and NLG919 (a direct IDO1 enzymatic inhibitor) that are indoleamine-2, 3-dioxygenase pathway inhibitors.
Open the LUMO Page at The Online Investor »

LUMO — Key Stats (updated 11 hours, 56 minutes ago)
Company Name:  Lumos Pharma Inc
Stock buyback:  LUMO buyback
Website:  www.lumos-pharma.com
Sector:  Drugs & Pharmaceuticals
Number of ETFs Holding LUMO:  2
Total Market Value Held by ETFs:  $583468
Total Market Capitalization:  $20.00M
% of Market Cap. Held by ETFs:  2.92%
 

Open the LUMO Page at The Online Investor (in a new window) »
April 18, 2024  •  10:50 PM Eastern
LUMO — Current Quote
Quotes delayed 20 minutes

Email EnvelopeFree LUMO Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts
Avg. Broker Rec.

Strong Buy (4.00 out of 4)
100th percentile
(ranked higher than approx. 100% of all stocks covered)

Analysts' Target Price:
LUMO Stock Forecast

 Based on Zacks ABR data;
powered by Xignite

LUMO Buyback | www.TheOnlineInvestor.com | Copyright © 1998 - 2024, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.